Key Highlights
- FDA greenlight received for Eli Lilly’s daily oral obesity medication orforglipron, marketed as Foundayo
- April 6 rollout through LillyDirect platform priced at $149 monthly for direct-paying patients
- Wall Street projects 2026 revenue between $1.5B (Guggenheim) and $2.8B (Citi), with long-term potential surpassing $40B annually
- Company stockpiled $1.5B in inventory ahead of launch to prevent shortages experienced with injectable treatments
- Consensus analyst price target stands at $1,221, with predominantly Buy or Moderate Buy recommendations
Eli Lilly has achieved a significant regulatory milestone with its oral GLP-1 medication. Federal regulators granted approval for orforglipron — marketed under the brand name Foundayo — representing the pharmaceutical giant’s inaugural daily pill for weight management and positioning it as a formidable competitor to Novo Nordisk’s market leadership.
During clinical testing, participants taking Foundayo experienced body weight reductions ranging from 12% to 15%. The medication operates through GLP-1 hormone receptor activation, employing the same biological pathway utilized by Novo’s Ozempic and Wegovy injectable formulations.
Commercial availability begins April 6 via the company’s LillyDirect distribution channel. Patients paying out-of-pocket can obtain the entry-level dosage for $149 monthly — a pricing strategy that mirrors Ozempic’s cost structure.
Chief Executive David Ricks announced that regulatory submissions for Foundayo have been filed in over 40 nations, indicating preparations for extensive global distribution are already underway.
Financial analysts have responded with optimism. Revenue projections for 2026 span from $1.5 billion to $2.8 billion, with Citi leading the bullish camp at $2.8B and forecasting peak yearly revenue potentially exceeding $40 billion. J.P. Morgan anticipates sales climbing to $6 billion by 2027.
Bernstein adopted a more reserved short-term perspective, noting that complimentary sampling programs, initial lower dosage protocols, and pricing pressures might suppress early revenue performance, despite potentially rapid prescription volume growth. Industry observers will closely monitor weekly new-patient enrollment figures.
Foundayo offers production advantages as well. The pill format presents fewer manufacturing complexities compared to injectable GLP-1 medications, potentially enabling Lilly to expand capacity more rapidly — especially in global markets where injectable supply has been constrained.
Supply Lessons Learned
Lilly reports accumulating $1.5 billion in pre-launch stock, a strategic move informed by availability problems that affected its injectable medications Zepbound and Mounjaro. These supply gaps created opportunities for U.S. compounding facilities to distribute alternative versions. Lilly subsequently initiated legal proceedings against compounders and wellness facilities marketing products purporting to contain tirzepatide.
Novo Nordisk is actively competing. The Copenhagen-based pharmaceutical company has countered with subscription-based pricing models and product modifications. UBS analysts estimate the combined oral product portfolios from both competitors could generate approximately $5 billion in 2026, highlighting rapid category expansion within obesity therapeutics.
Morningstar forecasts that oral obesity medications could represent approximately one-third of a $180 billion worldwide market by 2034.
Acquisition and Analyst Views
Lilly is simultaneously pursuing the acquisition of Centessa Pharmaceuticals through a transaction initially valued near $6.3 billion, broadening its portfolio into sleep-wake disorder and narcolepsy treatments. A legal firm has initiated an investor investigation regarding the Centessa transaction process, potentially creating complications before deal completion.
Regarding institutional activity, Westend Capital Management established a fresh LLY position during Q4, acquiring 16,393 shares valued at approximately $17.6 million. LLY currently represents roughly 4.9% of Westend’s holdings.
Lilly reported Q4 earnings per share of $7.54, surpassing expectations of $7.48, alongside revenue of $19.29 billion versus consensus estimates of $17.85 billion. Revenue increased 42.6% compared to the prior year. The company established fiscal 2026 EPS guidance ranging from $33.50 to $35.00.
Among 30 analysts tracking the stock, 23 assign Buy ratings, four recommend Hold, and one rates it Sell. The mean price target reaches $1,221.26.
